NexGel Inc (NXGL)
3.19
-0.10
(-3.04%)
USD |
NASDAQ |
Nov 14, 16:00
3.19
0.00 (0.00%)
After-Hours: 17:55
NexGel Research and Development Expense (Quarterly): 0.076M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.076M |
| March 31, 2024 | 0.002M |
| December 31, 2023 | 0.013M |
| September 30, 2023 | 0.006M |
| June 30, 2023 | 0.055M |
| March 31, 2023 | 0.029M |
| December 31, 2022 | 0.039M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.193M |
| June 30, 2022 | 0.111M |
| March 31, 2022 | 0.024M |
| December 31, 2021 | 0.014M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.01M |
| March 31, 2021 | 0.007M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2021
0.193M
Maximum
Sep 2022
0.0414M
Average
0.019M
Median
Research and Development Expense (Quarterly) Benchmarks
| The Cooper Companies Inc | 39.00M |
| Staar Surgical Co | 14.50M |
| OrthoPediatrics Corp | 2.577M |
| Innovative Eyewear Inc | 0.2568M |
| Perspective Therapeutics Inc | 9.275M |